control group, we analyzed blood donors with normal blood counts, normal values of liver enzymes and a negative serology for viral hepatitis and HIV. 24 In order to determine long-term outcome, we contacted the patients, their relatives and/or the general practitioner in approximately 6 months intervals after discharge from the hospital for 2 years. 
| Measurements of HMGB1 plasma levels
Blood samples were collected at the time of admission (before specific therapeutic measures), centrifuged, and plasma was stored at −80°C. Plasma HMGB1 concentrations were determined using a quantitative sandwich enzyme immunoassay (ELISA), according to manufacturer's instructions (HMGB1 ELISA, #ST51011; IBL International, Hamburg, Germany).
| Statistical analysis
Due to the skewed distribution of the parameters, data are given as median and range, and graphically displayed by box-and-whiskers plots. The degree of association between 2 variables was assessed by the Spearman rank correlation test. Comparisons of parameters between 2 different groups were conducted with the Mann-Whitney U-test. All values, including outside values as well as far out values, were included. The prognostic value of HMGB1 was explored using 3 groups, consisting of the patients with HMGB1 from the lowest quartile, from the middle 50% and from the highest quartile, by Kaplan Meier curves for ICU as well as for overall survival. 24 P-values less than .05 were considered as statistically significant. All analyses were performed with IBM SPSS Statistics (SPSS; Chicago, IL, USA).
| RE SULTS
3.1 | HMGB1 plasma levels are significantly elevated in critically ill patients as compared with healthy controls
High mobility group box 1 plasma levels were significantly elevated in a large cohort of 218 critically ill medical patients (median 10.37 ng/mL, range 0.25-80 ng/mL; Table 1 ) at admission to the ICU, as compared with 66 healthy controls (median 2.67 ng/mL, range 0.25-10.47 ng/mL, P < .001; Figure 1A ). Among the critically ill patients, there was no clear association between HMGB1 plasma concentrations and different disease aetiologies leading to ICU admission (data not shown).
| Elevated HMGB1 plasma levels in critically ill patients are independent of the presence of sepsis
Elevated HMGB1 have been previously reported in patients with bacteraemia, sepsis, and septic shock. [18] [19] [20] Within the cohort of ICU patients, HMGB1 levels did not differ between patients with sepsis (n = 146, median HMGB1 10.23 ng/mL, range 0.2-80 ng/mL) and patients without sepsis (n = 73, median 11.21 ng/mL, range 0.2-76.04 ng/mL; Figure 1B ). Typical sites of infection in sepsis were pneumonia, abdominal and urogenital tract, while non-sepsis causes of critical illness included, among others, cardiopulmonary diseases, acute pancreatitis and decompensated liver cirrhosis (detailed data not shown).
| HMGB1 plasma levels are not associated with disease severity or mechanical ventilation
Circulating HMGB1 has been previously suggested as a biomarker for disease severity in various clinical settings. 25 Plasma HMGB1
concentrations were not associated with disease severity, determined by the Acute Physiology And Chronic Health Evaluation-II (APACHE-II) score. Patients with a high APACHE-II score (above 10)
did not have higher HMGB1 levels than patients with an APACHE-II score below or equal to 10 ( Figure 1C ). In addition, there was also no significant difference in HMGB1 plasma levels between ventilated or non-ventilated critically ill patients (median 9.9 ng/mL vs median 11.5 ng/mL no ventilation, P = .492) ( Figure 1D ).
| Association of HMGB1 plasma levels in critically ill patients with metabolic and renal comorbidities
High mobility group box 1 has been associated with metabolic disorders. 26 , 27 We therefore assessed whether metabolic comorbidities, including pre-existing obesity or diabetes impacted HMGB1 levels at ICU admission. Interestingly, patients with pre-existing obesity, defined as a body mass index above 30 kg/m², showed a trend toward lower HMGB1 levels at ICU admission (median 5.93 ng/mL vs median 11.6 ng/mL in non-obese patients, P = .052) (Figure 2A ).
Patients with pre-existing type 2 diabetes have slightly lower TA B L E 1 Baseline patient characteristics and HMGB1 plasma measurements HMGB1 levels (median 8.29 ng/mL in diabetics vs median 11.1 ng/ mL in non-diabetics, not significant; Figure 2B ). This finding corresponds to the inverse correlation between HMGB1 and blood glucose at ICU admission (Table 2) .
We next investigated the potential association between HMGB1
and renal diseases, based on its involvement in chronic renal disorders. 28 A small subgroup of our cohort consisted of end-stage renal disease patients requiring chronic hemodialysis (n = 9). These F I G U R E 1 HMGB1 levels in critically ill patients. A, HMGB1 plasma concentrations are significantly elevated in critically ill patients compared with healthy controls. B, HMGB1 levels do not differ between intensive care unit (ICU) patients with or without sepsis. C, High disease severity, as defined by an APACHE-II score above 10, is not associated with elevated plasma HMGB1. D, The need of mechanical ventilation was not associated with HMGB1 levels at ICU admission. P-values (U-test) are given in the figure. HMGB1, high mobility group box 1 F I G U R E 2 Impact of metabolic comorbidities on HMGB1 levels. HMGB1 plasma concentrations did not differ between ICU patients with or without obesity, as defined by a body-mass index (BMI) above 30 kg/m 2 (A), pre-existing type 2 diabetes (B) or pre-existing end-stage renal disease (ESRD, C). HMGB1, high mobility group box 1; ICU, intensive care unit patients showed a clear trend toward lower HMGB1 levels at ICU admission (median 3.4 ng/mL in patients with vs median 9.9 ng/mL in patients without chronic renal replacement therapy, P = .259) ( Figure 2C ). However, in the whole cohort of critically ill patients, we did not observe a correlation between HMGB1 and classical markers of renal failure, such as creatinine or cystatin C. HMGB1, however, correlated inversely with urea, likely reflecting renal function, metabolism, and nutritional status (Table 2) .
| High HMGB1 plasma concentrations at ICU admission are not associated with adverse prognosis
In critically patients, who subsequently died during the ICU treatment (n = 49), we did not find significantly altered HMGB1 levels at admission to the ICU, suggesting that HMGB1 is not a prognostic biomarker in critical diseases. 16 Nevertheless, we observed a trend toward increased HMGB1 levels in the deceased patients compared to the surviving patients (median 12.89 ng/mL vs median 9.65 ng/ mL in ICU survivors) ( Figure 3A) , while there was no significant difference for the overall mortality either ( Figure 3B ). By KaplanMeier curve analysis, patients with HMGB1 levels of the highest quartile (>19.2 ng/mL) showed a tendency toward improved ICU ( Figure 3C ) or overall survival ( Figure 3D ), but did not reach statistical significance. Animal models supported the hypothesis that circulating HMGB1
| D ISCUSS I ON
is involved in the pathogenesis of sepsis. 7 However, unlike classical inflammatory cytokines (eg, TNF), an increase in HMGB1 is not observed within the first hours after sepsis induction, but was a characteristic of the late phase of sepsis associated with lethality. 14, 15, [32] [33] [34] In turn, neutralization of HMGB1 during the late phase of sepsis using specific antibodies prevented rodents from sepsisrelated death. 33, 35 Based on its pathogenic role, circulating HMGB1
has been suggested as a biomarker for the assessment of sepsis, disease severity and mortality. 6, 16, 17 However, our study with a prospectively enrolled, large and heterogeneous cohort of critically ill medical patients clearly demonstrated that HMGB1 has limited value as a biomarker in the ICU setting. Although we did confirm elevated HMGB1 plasma levels in critically ill patients as compared to healthy controls, in line with previous reports, [18] [19] [20] HMGB1 (sampled at ICU admission) was not an indicator of disease severity, organ failure, or mortality. Even more surprising, patients with sepsis did not display different HMGB1
concentrations as compared to ICU patients without sepsis. Earlier studies from Denmark that included 194 and 185 patients had found higher levels of HMGB1 in infectious vs non-infectious diseases.
18,36
On the contrary, HMGB1 was not able to discriminate sepsis from non-infectious disease in the setting of an Emergency Department, as identified in a cohort of 631 patients with heterogeneous diseases. 37 Similar controversies have been reported regarding the potential association of HMGB1 to disease severity and mortality.
HMGB1 was reported to be elevated in patients with severe sepsis and septic shock compared to patients with sepsis, 19, 36 but did not differ between survivors or non-survivors in an observational study that included 247 patients from 24 ICUs in Finland. 19 Interestingly, while HMGB1 levels at ICU admission did not predict mortality in a
French study on 42 critically ill patients with septic shock, HMGB1 levels at day 3 were able to discriminate between survivors and nonsurvivors in a medical ICU setting. 20 In a study from the Karolinska institute that analyzed 64 patients (including 33 with septic shock), HMGB1 remained high in patients for 1 week after ICU admission, 16 supporting that HMGB1 is a downstream and late mediator of inflammation. Thus, the lack of clinical utility as a biomarker in the early phase of critical disease at ICU admission, as demonstrated by our study, does not preclude its potential value in later phases of the clinical course. Future studies should particularly focus on longitudinal measurements of HMGB1 in the ICU.
In addition, circulating HMGB1 in patient's plasma might not necessarily reflect the full biological activity during critical illness.
On the one hand, local concentrations in ischemic or injured tissue might be higher-and immediately bind to TLR2, TLR4 or RAGE on local macrophages. 25 On the other hand, a 30-kDa low molecular weight HMGB1 variant was detected in sepsis patients, 5, 14 Nonetheless, it is important to note the limitations of our study. We conducted a monocentric, observational study with relatively broad inclusion criteria. While this reflects a "real-world situation" of critically ill patients at a medical ICU, it introduces a substantial heterogeneity regarding patient characteristics, and therefore, resulting in relatively small subgroups, which may be underpowered for further subgroup analyses. Due to the prospective inclusion study design with an uncertain further course in the ICU, a substantial fraction of the patients had a rather low APACHE-II score, which may have reduced the discriminant role of HMGB1 in our cohort.
| CON CLUS ION
In conclusion, we herein demonstrated significantly elevated 
